ARF7 Inhibitors
ARF7 inhibitors are chemical entities designed to attenuate the functional activity of ARF7 by impinging on various signaling mechanisms and cellular pathways with which ARF7 is intimately associated. Brefeldin A, for instance, exerts its inhibitory effect by binding to ARF-GEFs, thereby preventing the activation of ARF7, which is pivotal for vesicular transport processes. Golgicide A achieves a similar outcome by selectively targeting GBF1, a GEF with potential implications on ARF7 activity, leading to the disruption of the Golgi apparatus and ARF7's role in Golgi-dependent trafficking. SecinH3 and QS11 follow suit in the inhibition narrative, with SecinH3 hindering ARF7's GEFs, impairing the endocytic recycling where ARF7 is involved, and QS11 obstructing Wnt/β-catenin signaling, consequently impacting ARF7-mediated cell migration and invasion by inhibiting ARNO.
The modulation of ARF7 activity extends to compounds like S107 and 4E1RCat, which target the Sec7 domain, consequently impeding the GDP-GTP exchange on ARF7 and attenuating ARF7's influence on cytoskeletal dynamics and vesicle trafficking. AG1478, though an EGFR tyrosine kinase inhibitor, indirectly impacts ARF7 by stymieing upstream EGFR signaling that can activate ARF-GEFs, thus potentially reducing ARF7 activation. Complementarily, Sorafenib, Fluvastatin, and Vismodegib each indirectly diminish ARF7's function by inhibiting Cdc42 GTPase, Rho GTPase, and phospholipase D, respectively, all of which are elements of signaling pathways that affect ARF7's regulatory scope on the cytoskeleton and vesicular trafficking. Dynasore and EPZ005687 round off the list by targeting dynamin and clathrin-mediated endocytosis, both crucial for endocytic pathways where ARF7 is a key player, ensuring a comprehensive downregulation of ARF7's cellular roles.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Brefeldin A | 20350-15-6 | sc-200861C sc-200861 sc-200861A sc-200861B | 1 mg 5 mg 25 mg 100 mg | $30.00 $52.00 $122.00 $367.00 | 25 | |
Brefeldin A is an inhibitor of ADP-ribosylation factor (ARF) proteins, including ARF7, by blocking the activation of ARF proteins. It does so by inhibiting guanine nucleotide exchange factors (GEFs), leading to the inactivation of ARF7 and subsequent inhibition of ARF7-mediated transport processes. | ||||||
Golgicide A | 1005036-73-6 | sc-215103 sc-215103A | 5 mg 25 mg | $187.00 $670.00 | 11 | |
Golgicide A specifically inhibits Golgi BFA resistance factor 1 (GBF1), a GEF for ARF1 and potentially ARF7, resulting in the disruption of Golgi structure and function and thereby diminishing ARF7's role in Golgi-dependent trafficking. | ||||||
SecinH3 | 853625-60-2 | sc-203260 | 5 mg | $273.00 | 6 | |
SecinH3 is a cytohesin inhibitor that interferes with the activation of ARF6 and potentially ARF7 by inhibiting their GEFs, leading to reduced ARF7-mediated endocytic recycling. | ||||||
4E1RCat | 328998-25-0 | sc-361085 sc-361085A | 10 mg 50 mg | $189.00 $797.00 | ||
4E1RCat is a small molecule inhibitor of Sec7 domains of ARF GEFs, which likely includes effects on ARF7. It disrupts the formation of the Golgi apparatus and vesicular trafficking pathways, thereby diminishing ARF7's role in these processes. | ||||||
Tyrphostin AG 1478 | 175178-82-2 | sc-200613 sc-200613A | 5 mg 25 mg | $94.00 $413.00 | 16 | |
AG1478 is an EGFR tyrosine kinase inhibitor that indirectly affects ARF7 by inhibiting EGFR signaling, which is known to interact with ARF-GEFs and could, therefore, lead to decreased ARF7 activity by limiting upstream activation signals. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $56.00 $260.00 $416.00 | 129 | |
Sorafenib is a selective and reversible inhibitor of Cdc42 GTPase, which can indirectly affect ARF7-dependent actin cytoskeleton organization and vesicular trafficking by altering downstream signaling pathways that involve ARF7. | ||||||
Fluvastatin | 93957-54-1 | sc-279169 | 50 mg | $250.00 | ||
Fluvastatin is a selective inhibitor of Rho GTPases, which indirectly diminishes ARF7 activity by influencing the actin cytoskeleton and cell migration processes that ARF7 is known to affect. | ||||||
Vismodegib | 879085-55-9 | sc-396759 sc-396759A | 10 mg 25 mg | $80.00 $96.00 | 1 | |
Vismodegib is a phospholipase D inhibitor that can potentially diminish ARF7 activity by inhibiting the production of phosphatidic acid, which is essential for ARF-mediated vesicle trafficking. | ||||||
Dynamin Inhibitor I, Dynasore | 304448-55-3 | sc-202592 | 10 mg | $87.00 | 44 | |
Dynasore is a GTPase inhibitor that targets dynamin, which indirectly can lead to the diminished function of ARF7 by inhibiting endocytic pathways that ARF7 is involved in. | ||||||
EPZ005687 | 1396772-26-1 | sc-497734 | 2.5 mg | $380.00 | ||
EPZ005687 is an inhibitor of clathrin-mediated endocytosis, which can indirectly reduce ARF7 activity by blocking a key pathway in which ARF7 functions, thus diminishing its role in intracellular trafficking. | ||||||